UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000050033
Receipt number R000056999
Scientific Title Investigation of the effects of test-food intakes on gut environment
Date of disclosure of the study information 2023/01/13
Last modified on 2023/07/19 14:50:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of the effects of test-food intakes on gut environment

Acronym

Investigation of the effects of test-food intakes on gut environment

Scientific Title

Investigation of the effects of test-food intakes on gut environment

Scientific Title:Acronym

Investigation of the effects of test-food intakes on gut environment

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In order to investigate some kind of effect on gut environment by the test-food ingestion for 12 weeks.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Defecation status questionnaire (the number of days, frequency, quantity, property, color, feeling of incomplete evacuation, abdominal pain, fecal odor)

Key secondary outcomes

1. Gut microbiota
2. Gut metabolites
3. QOL questionnaire
4. Sleep status questionnaire
5. Questionnaire about skin


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Consumption of the test drink (50 mL per day) every day for 12 weeks.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

(1) At informed consent, male/female subjects aged more than or equal to 20, and less than 80 years old.
(2) Subjects who can show understanding of the study procedures and agreement with participating in the study by written informed consent prior to the study.

Key exclusion criteria

(1)Subjects who have consumed fermented plant beverages and foods containing fermented plant extracts within the last 1 month to the study start, or have a plan to consume it during this study.
(2)Subjects who are regularly consuming foods for specified health uses, foods with function claims, supplements and/or health foods for more than 3 times a week, which would affect the study results.
(3)Subjects who have current medical history/anamnesis of immune-related diseases such as autoimmune diseases or digestive ones.
(4)Pregnant, possibly pregnant, or lactating women.
(5)Subjects who have an allergy to the test food.
(6)Subjects who have been determined ineligible for participation, judging from the principal investigator's opinions.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name Shinnosuke
Middle name
Last name Murakami

Organization

Metagen, Inc.

Division name

Headquarters

Zip code

9970052

Address

246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan

TEL

+81-235-64-0330

Email

research@metagen.co.jp


Public contact

Name of contact person

1st name Shinnosuke
Middle name
Last name Murakami

Organization

Metagen, Inc.

Division name

Headquarters

Zip code

9970052

Address

246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, Japan

TEL

+81-235-64-0330

Homepage URL


Email

research@metagen.co.jp


Sponsor or person

Institute

Metagen, Inc.

Institute

Department

Personal name



Funding Source

Organization

ARSOA KEIO GROUP CORPORATION

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Pharmaceutical Law Wisdoms

Address

5F, 4-3-17 Shinjuku, Shinjukuku, Tokyo

Tel

+81-3-6457-4911

Email

master@yakujihou.net


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 01 Month 04 Day

Date of IRB

2022 Year 12 Month 22 Day

Anticipated trial start date

2023 Year 01 Month 17 Day

Last follow-up date

2023 Year 05 Month 05 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 01 Month 13 Day

Last modified on

2023 Year 07 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056999


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name